৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Products
Payment
Delivery
Indications
Corlift is indicated to reduce the risk of cardiovascular doath and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic
HF and ejection fraction less than 456.
Pharmacology
Vericiguat is a stimulator of soluble guanylate cyclase (sBC), an important enzyme in the nitric oxide (ND) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic
guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, and cardiac contractility, and cardiac remodeling. Hoart failure is associated with impaired synthesis of
NO and decreased activity of sGC, which may contribute to myocardial and vascular dystunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of
intracellular cGMP, loading to smooth muscle relaxation and vasodilation.
Dosage & Administration
Recommended Starting Dose: The recommended starting dose of Vericiguat is 2.5 mg orally once daily with food. Double the dose of Vericiguat approximately every 2 weeks to reach the target maintenance
dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablet, Vericiguat may be crushed and mixed with water immediately before administration or as directed by
physician.
Geriatric Patients: No dosage adjustment of Vericiguat is required in geriatric patients. No overall differences in safety or efficacy of Vericiguat were observed between patients aged 65 yoars and older
compared to younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Hepatie Impairment: No dosage adjustment of Vericiguat is recommended in patients with mild or moderate hepatic impairment.
Renal Impairment: No dosage adjustment of Vericiguat is recommended in patients with estimated glomerular filtration rate [eGFR) 215 mL/min/1.73m2 who are not on dialysis. Vericiguat has not been studied in
patients with eGFR <15 mL/min/173m2 at treatment initiation or on dialysis.
Use in Children & Adolescents: Satety and effectiveness of Vericiguat have not been established in pediatric patients.
Interaction
Other Soluble Guanylate Cyclase Stimulators: Corlift is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
PDE-5 Inhibitors: Concomitant use of Corlift with PDE-5 inhibitors is not recommended because of the potential for hypotension.
With food & others: Corlift should be takan with food. The absolute bioavailabiity of Corlift is 93% when taken with food.
Contraindications
Vericiguat is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sBC) stimulators.
Side Effects
Common Side effects: The most common side effeets of Corlift tablet include low blood pressure & low red blood cells (Anemia).
Pregnancy & Lactation
Pregnancy: Vericiguat is contraindicated in pregnancy because it may cause fetal harm. Exclude pregnancy betore the start of treatment. To prevent pregnancy, females of reproductive potential must use
effective forms of contraception during troatment and for one month after stopping treatment.
Nursing Mothers: There are no data on the presence of Vericiguat in human milk, the effects on the breastfed infant, or the effeets on milk production. Because of the potential for serious adverse reactions in
breastfed infants from Vericiguat, women should be advised not to breastfeed during treatment with Vericiguat.
Precautions & Warnings
Corlift should not be administered to a pregnant female bocause it may cause fetal harm. Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with Corlift. Pregnancy should
be excluded before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective fors of contraception during treatment and for one month after stopping treatmant.
Overdose Effects
Limited data are available with regard to overdosage in human patients treated with Corlift. Doses up to 10 mg have been studied. In a study of pationts with preserved ejection fraction heart failure fleft
ventricular ejection fraction 245%), multiple doses of Corlift 15 mg have been studied and were generally well tolerated. In the event of an overdose, hypotension may result. Symptomatic treatment should be
provided. Corlift is unlikely to be removed by hemodialysis because of high protein binding.
Therapeutic Class
Stimulator of soluble guanylate cyclase
Storage Conditions
Keep below 30"C temperature, away from light & moisture. Keep out of the reach of children.





Vericiguat tablet is used to treat adults who are experiencing a recent worsening of long-term heart failure symptoms.
N/A

